Mastoparan
is an amphiphilic tetradecapeptide isolated from wasp venom which has been reported to exhibit diverse pharmacological effects in several cell types. These include the activation of phospholipase A, in vitro [l], anticalmodulin activity [2] , inhibition of phospholipase C [3] , and the ability to promote exocytosis [2!4] -Current interest in this agent has arisen -from recent studies demonstrating its ability to accelerate nucleotide exchange and GTPase activity of several purified GTPbinding proteins (G proteins) in a manner analogous to agonist-liganded receptors [5] . As such, mastoparan has potential value as a biochemical tool for investigating G proteindependent events in secretory tissues. In the present study we have examined in detail the functional consequences of exposure of human platelets to mastoparan (MP).
Platelet aggregation, 5-hydroxytryptamine (5-HT) secretion, liberation of arachidonic acid (AA), beta-thromboglobulin (BTG) release and protein phosphorylation were measured in washed human platelets prepared from citrate anticoagulated blood using previously described procedures [6] . Intracellular CAMP levels ([CAMP],) were monitored using a modification of the procedure described by Gilman [7] . To obtain measurements of phosphoinositide turnover platelets were loaded with [ 'Hlinositol during reversible electropermeabilisation as described by Authi et al. [8] . Inositol phosphate analysis was performed according to the method of Downes and Wusteman [9] . Mastoparan was synthesised, and purified by reverse phase hplc.
In [ 14C ] 5-HT and ['HI AA-labelled platelets, exposure to MP at concentrations ranging between 1 and 35 uM promoted a dose-dependent increase in 5-HT secretion which was evident within a 1 min stimulation period, was not enhanced further with extended incubation times, and was insensitive to the protein kinase inhibitor staurosporine (50 nM) . MP at 1 , 10 and 30 uM gave 1.4 + 0.7, 13.2 + 1.0 and 37.7 + 2.8 % 5-HT release (mean i SEM., n = 4). Secretion from alpha granules, as assessed by BTG release, also occurred within 1 min stimulation and was detectable with MP concentrations as low as 1 UM (10 + 2 % total content). These secretory events were not due to cell lysis since (i) MP caused no release of adenine metabolites from platelets prelabelled with ['Hladenine, and (ii) fura 2-loaded platelets stimulated with MP exhibited no decrease in fluorescence at 360 nm, an event which is associated with membrane leakiness. Although MP clearly caused exocytosis, no significant liberation of ['HIAA was detected over the same MP concentration range. Similarly, no measurable Ca" mobilisation was observed in either quin 2 or fura 2-loaded platelets exposed to MP.
In [ "PI-labelled platelets no detectable phosphorylation of the 45 and 2OkDa polypeptides (substrates for PKC and myosin light chain kinase respectively) was observed with MP (10 sec-5 min). MP did, however, reduce both thrombin-and fluoride-induced 45kDa phosphorylation without affecting that caused by phorbol myristate acetate (PMA) . In platelets prelabelled with ['Hlinositol during reversible electropermeabilisation, MP did not elevate inositol phosphate (IP) production above that seen in resting platelets and had no measurable effect on thrombin-induced IP formation.
The effect of MP on platelet [CAMP], levels was also examined. In intact platelets, MP (1-30 uM) elevated [CAMP] , to levels equal to or greater than those induced by prostacyclin ( (PGI,; 5-100 ng/ml) . Moreover, MP showed no ability to reduce PG1,-stimulated CAMP but showed an additive effect on cellular CAMP and enhanced ["PI incorporation into proteins of molecular weights approximating 22 and 24kDa.
In conclusion, MP is an interesting agent that exhibits both stimulatory and inhibitory effects on human platelets. It induces secretion by an unknown mechanism which is independent of phospholipase C, insensitive to staurosporine and does not involve phosphorylation of the 45 and 2OkDa protein substrates normally associated with platelet activation. In fact, MP inhibits both thrombin-and fluoride-(but not PMA-) induced phosphorylation of these susbstrates but not thrombin-induced IP formation. These inhibitory effects may be related to the increased CAMP levels induced by MP and to the associated phosphorylation of CAMPdependent protein kinase substrates. Financial support from the MRC and The Wellcome Trust is gratefully acknowledged.
